



(II).

[012] Also provided is a composition comprising a compound of structural formula I:




(I),

or a salt thereof, wherein the composition contains a detectable amount of about 0.20% or less of a compound of structural formula XIII:




(XIII).

[013] Also provided is a composition comprising a compound of structural formula I:




(I),

or a salt thereof, wherein the composition contains a detectable amount of about 0.20% or less of a compound of structural formula XIV:




(XIV).

[013a] In one aspect, the present disclosure refers to a composition comprising a compound of structural formula I:




(I),

or a salt thereof, wherein the composition contains a non-detectable amount of a compound of structural formula II:




(II),

wherein the composition contains a detectable amount of about 0.20% or less of a compound of structural formula XIII:



(XIII), and

wherein the composition contains a detectable amount of about 0.20% or less of a compound of structural formula XIV:



(XIV).

[014] In one aspect, the present disclosure refers to a pharmaceutical composition comprising a composition of described herein, and a pharmaceutically acceptable carrier.

[015] Also provided is a method for treating a HSD-1-mediated disorder in a subject in need thereof, comprising the step of administering to the subject a therapeutically effective amount of the composition or pharmaceutical composition described herein.

[015a] In one aspect, the present disclosure refers to use of the composition disclosed herein, in the manufacture of a medicament for treating a HSD-1-mediated disorder in a subject in need thereof.

[015b] In one aspect, the present disclosure refers to use of the pharmaceutical composition disclosed herein, in the manufacture of a medicament for treating a HSD-1-mediated disorder in a subject in need thereof.

[016] Also provided is a method for treating GC excess, or a condition thereof, in a subject in need thereof, comprising the step of administering to the subject a therapeutically effective amount of the composition or pharmaceutical composition described herein. Conditions of GC excess include Cushing's syndrome and autonomous cortisol secretion. GC excess may also be caused by the use of one or more GC medications.

[016a] In one aspect, the present disclosure refers to use of the composition disclosed herein, in the manufacture of a medicament for treating glucocorticoid excess, or a condition thereof, in a subject in need thereof.

[016b] In one aspect, the present disclosure refers to use of the pharmaceutical composition disclosed herein, in the manufacture of a medicament for treating glucocorticoid excess, or a condition thereof, in a subject in need thereof.

[017] These and other aspects of the disclosure disclosed herein will be set forth in greater detail as the patent disclosure proceeds.

DETAILED DESCRIPTION

Abbreviations and Definitions

[018] To facilitate understanding of the disclosure, a number of terms and abbreviations as used herein are defined below as follows:

[019] When introducing elements of the present disclosure or the preferred embodiment(s) thereof, the articles "a", "an", "the" and "said" are intended to mean that there are one or more of the elements. The terms "comprising", "including" and "having" are intended to be inclusive and mean that there may be additional elements other than the listed elements.

[020] When ranges of values are disclosed, and the notation "from n_1 … to n_2" or "between n_1 … and n_2" is used, where n_1 and n_2 are the numbers, then unless otherwise specified, this notation is intended to include the numbers themselves and the range between them. This range may be integral or continuous between and including the end values. By way of example, the range "from 2 to 6 carbons" is intended to include two, three, four, five, and six carbons, since carbons come in integer units. Compare, by way of example, the range "from 1 to 3 μM (micromolar)," which is intended to include 1 μM, 3 μM, and everything in between to any number of significant figures (e.g., 1.255 μM, 2.1 μM, 2.9999 μM, etc.).

[021] The term "about," as used herein when referring to a measurable value such as an amount of a compound, dose, time, temperature, and the like, is meant to encompass variations of 20%, 10%, 5%, 1%, 0.5%, or even 0.1% from the specified amount.

[022] The term "detectable" refers to a measurable quantity measured using an HPLC method having a detection limit of 0.05 area %.

[023] The term "chlorinating reagent," as used herein, refers to a compound or salt that adds a chlorine atom or atoms to an organic compound in a chemical reaction.